Anna Quattropani, PhD, is the head of medicinal chemistry at Asceneuron. Dr. Quattropani obtained her MS and PhD in organic synthesis and organometallic chemistry at the University of Geneva in Switzerland. She completed her postdoctoral training at the University of California in Irvine, California in the laboratory of Larry E. Overman.

Dr. Quattropani has more than 17 years of experience and a successful track record in the design and optimization of small molecules originating from HTS, fragment discovery or knowledge-based design into drug candidates. Over the past ten years, she has worked on a variety of neurodegenerative disease projects, designing and optimizing drug-like small molecules with CNS exposure for multiple sclerosis and Alzheimer’s disease therapeutics. She has successfully delivered preclinical candidates for progressive supranuclear palsy (O-GlcNAcase inhibitor), multiple sclerosis and an oxytocin receptor antagonist that has entered Phase II testing. Dr. Quattropani also holds 32 patents and has authored 20 peer-reviewed publications.